特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
965933

COVID-19抗原診断テスト情勢:2021年までの予測

COVID19 Antigen Diagnostic Test Landscape | Forecasts Through 2021

出版日: | 発行: Life Science Intelligence | ページ情報: 英文 30 Pages; 10 Exhibits | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.89円
COVID-19抗原診断テスト情勢:2021年までの予測
出版日: 2020年10月12日
発行: Life Science Intelligence
ページ情報: 英文 30 Pages; 10 Exhibits
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

COVID-19診断検査の世界の市場は、2020年に160億米ドルとなり、2020年から2025年の間に6.5%のCAGRで成長すると予測されています。市場は、分子検査、抗原検査、および抗体検査に分割されます。

抗体検査の当初の需要は、無症候性および症候性の現在の感染症例に焦点を当てる保健当局からのガイダンスのシフトにより沈静化しまし、WHOは低・中所得国に1億2,000万件の迅速なCOVID-19検査を提供すると発表した。また、AbbottとRocheは迅速抗原検査の生産を拡大しており、2種の迅速抗原検査をそれぞれ月産5000万件以上生産する予定です。

当レポートは、世界のCOVID-19抗原診断検査市場について調査しており、COVID-19抗原診断検査別の市場分析、臨床試験、規制当局の承認、競合情勢などの情報を提供しています。

当レポート調査対象の企業:

  • Abbott
  • Abbott Diagnostics Scarborough, Inc.
  • Access Bio, Inc
  • AmonMed Biotechnology Co., Ltd
  • AMS UK Ltd.
  • Apollo Biomedical LLC
  • ArcDia International Ltd.
  • Becton, Dickinson and Company (BD)
  • Beijing Abace Biology Co. Ltd
  • Beijing Diagreat Biotechnologies Co., Ltd
  • Beijing Kewei Clinical Diagnostic Reagent Inc.
  • Beijing Savant Biotechnology Co., Ltd
  • BIOHIT HealthCare (Hefei) Co., Ltd
  • Bionote Inc.
  • Boditech Inc.
  • Cepheid
  • CerTest Biotec S.L.
  • Coris BioConcept
  • DiaSorin
  • Edinburgh Genetics Limited
  • GenBody, Inc.
  • Green Cross Medical Science Corp.
  • Hangzhou Deangel Biological Engineering Co., Ltd
  • Hangzhou Genesis Biodetection & Biocontrol Co., Ltd
  • Hologic
  • Humasis
  • Jiangsu Bioperfectus Technologies Co. Ltd
  • JOYSBIO (Tianjin) Biotechnology Co., Ltd
  • Liming Bio-Products Co., Ltd
  • LumiQuick Diagnostics Inc.
  • LumiraDx UK Ltd.
  • Medisys International SA
  • nal von minden GmbH
  • PCL Inc.
  • Precision Biosensor, Inc.
  • Qiagen
  • Quidel Corporation
  • RapiGEN Inc.
  • Roche
  • SD BIOSENSOR, Inc.
  • Shenzhen Bioeasy Biotechnology Co., Ltd
  • ThermoFisher

目次

市場概要

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 セグメンテーション

  • COVID-19抗原診断検査リスト
  • サンプルタイプ別
    • 鼻咽頭(NP)スワブ
    • 中咽頭(OP)スワブ
    • 鼻腔スワブ
    • 血液
    • その他
  • 手法別
    • 分子(PCR)
    • 抗原ベース
    • その他
  • 動作モード別
    • ポイントオブケア(POC)
    • ラボ

第4章 臨床試験

  • ステータス別
  • ロケーション別
  • スポンサー別

第5章 規制当局の承認

  • FDA承認
  • CE承認

第6章 競合情勢(主要企業)

目次

Overview:

The global market for COVID19 Diagnostic Tests was valued at $16B in 2020 and is expected to grow at a CAGR (2020-2025) of 6.5%. The market is segmented into molecular tests, antigen tests, and antibody tests.

Molecular diagnostic tests to diagnose COVID19 were available in the USA a few months after the outbreak in China. On February 4, 2020, the US FDA issued an emergency use authorization (EUA) enabling the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel. Since then authorized molecular laboratories, molecular diagnostic companies, and in-vitro diagnostic companies have developed several COVID19 diagnostic tests. The U.S. FDA has authorized more than 262 coronavirus diagnostic tests under EUAs, which include 205 molecular tests, 51 antibody tests, and 6 antigen tests.

In this new report, LSI provides timely coverage and an assessment of the market opportunities for COVID19 diagnostic tests. The initial demand for antibody tests has subsided due to a shift in the guidance from health authorities to focus on asymptomatic and symptomatic current infection cases. The WHO announced it will provide 120 million rapid COVID-19 tests to low-and middle-income countries. Abbott and Roche have scaled their production of rapid antigen tests and are expected to produce more than 50 million tests per month of BinaxNOW™ COVID-19 Ag Card and STANDARD Q SARS-CoV-2 Rapid Antigen Test respectively. Additionally, Point of Care (POC) antigen tests Veritor™ Plus System from BD, LumiraDx Sars-CoV-2 Ag from LumiraDx, and Sofia SARS Antigen Test were issued FDA EUA and will augment the rapid testing capabilities at hospitals and near-patient CLIA waived settings.

Combination tests that detect common flu A, B, and COVID19 are in demand ahead of the flu season. SARS-CoV-2 and influenza A/B test from Roche and Xpert Xpress SARS-CoV-2, influenza A and B, and respiratory syncytial virus (RSV) from Cepheid (Danaher Company) has been issued FDA EUA.

This report provides data and insight for healthtech executives seeking:

  • Informed decisions for new product development
  • Evaluation of technology transfer opportunities
  • Manufacturing and distribution opportunities
  • Thorough evaluation of progress of vaccine clinical trials
  • Competitive landscape assessment
  • More

Companies Covered:

  • Abbott
  • Abbott Diagnostics Scarborough, Inc.
  • Access Bio, Inc
  • AmonMed Biotechnology Co., Ltd
  • AMS UK Ltd.
  • Apollo Biomedical LLC
  • ArcDia International Ltd.
  • Becton, Dickinson and Company (BD)
  • Beijing Abace Biology Co. Ltd
  • Beijing Diagreat Biotechnologies Co., Ltd
  • Beijing Kewei Clinical Diagnostic Reagent Inc.
  • Beijing Savant Biotechnology Co., Ltd
  • BIOHIT HealthCare (Hefei) Co., Ltd
  • Bionote Inc.
  • Boditech Inc.
  • Cepheid
  • CerTest Biotec S.L.
  • Coris BioConcept
  • DiaSorin
  • Edinburgh Genetics Limited
  • GenBody, Inc.
  • Green Cross Medical Science Corp.
  • Hangzhou Deangel Biological Engineering Co., Ltd
  • Hangzhou Genesis Biodetection & Biocontrol Co., Ltd
  • Hologic
  • Humasis
  • Jiangsu Bioperfectus Technologies Co. Ltd
  • JOYSBIO (Tianjin) Biotechnology Co., Ltd
  • Liming Bio-Products Co., Ltd
  • LumiQuick Diagnostics Inc.
  • LumiraDx UK Ltd.
  • Medisys International SA
  • nal von minden GmbH
  • PCL Inc.
  • Precision Biosensor, Inc.
  • Qiagen
  • Quidel Corporation
  • RapiGEN Inc.
  • Roche
  • SD BIOSENSOR, Inc.
  • Shenzhen Bioeasy Biotechnology Co., Ltd
  • ThermoFisher

Table of Contents

Global COVID19 Antigen Diagnostic Tests Market Overview

1. Executive Summary

2. Scope Of The Report

3. COVID19 Antigen Diagnostic Tests Segmentation

  • 3.1. COVID19 Antigen Diagnostic Tests List (Brief Commentary on Strengths & Weaknesses)
  • 3.2. COVID19 Antigen Diagnostic Tests By Sample Type
    • Nasopharyngeal (NP) Swab
    • Oropharyngeal (OP) Swab
    • Nasal Swab
    • Blood
    • Others
  • 3.3. COVID19 Antigen Diagnostic Tests By Method
    • Molecular (PCR) Testing
    • Antigen-based Testing
    • Others
  • 3.3. COVID19 Antigen Diagnostic Tests By Mode of Operation
    • Point of Care (POC)
    • Laboratory

4. COVID19 Antigen Tests Clinical Trials

  • 4.1. By Status
  • 4.2. By Location
  • 4.3. By Sponsor

5. Regulatory Approval

  • 5.1. FDA Approved COVID19 Antigen Tests
  • 5.2. CE Approved COVID19 Antigen Tests

6 COVID19 Antigen Diagnostic Tests Competitive Landscape (Key Companies)

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.